DECLARE, being the largest cardiovascular-outcome-trial with SGLT2 inhibitors [116], included over 10,000 T2D patients with cardiovascular risk factors but without established cardiovascular disease, with relatively normal kidney function tests (48% with eGFR > 90 mL/min/1.73 m2 and 45% with eGFR 60–90 mL/min/1.73 m2, while only 7% were with eGFR < 60 mL/min/1.73 m2). This evidence concerns the gene SLC5A2 and cardiovascular disorder.